Stock MRNS MARINUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
1.43 USD -8.92% Intraday chart for Marinus Pharmaceuticals, Inc. -2.72% -86.84%
May. 08 Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M MT
May. 08 Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
AQ
Marinus Pharmaceuticals: Q1 Earnings Snapshot
AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
BU
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
BU
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
BU
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review
AQ
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
BU
Marinus Pharmaceuticals: Q4 Earnings Snapshot
AQ
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
BU
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
BU
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY Net Product Revenue and Provides Business Update
AQ
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
BU
Marinus Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNS Stock
  4. News Marinus Pharmaceuticals, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW